Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNB2 | O95067 | 1/20 | 0.36 |
| ▸ | CDK1 | P06493 | 1/20 | 0.36 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.36 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.36 |
| ▸ | FDPS | P14324 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.34 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.34 |
| ▸ | CYP4Z1 | Q86W10 | 4/20 | 0.34 |
| ▸ | ASAH1 | Q13510 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 3/20 | 0.32 |
| ▸ | DNM2 | P50570 | 2/20 | 0.32 |
| ▸ | LTA4H | P09960 | 1/20 | 0.32 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10779053 | 0.99 | ALDH1A1 (0.37) | CCNB2CDK1CCNB1CCNB3FDPS | |
| SCHEMBL8653897 | 0.95 | FDPS (0.37) | CCNB2CDK1CCNB1CCNB3FDPS | |
| SCHEMBL5934357 | 0.89 | FDPS (0.38) | FDPSALDH1A1HDAC1HDAC6LMNA | |
| SCHEMBL29060875 | 0.85 | FDPS (0.36) | FDPSHDAC1HDAC6LTA4H | |
| SCHEMBL29060890 | 0.82 | FDPS (0.38) | FDPSHDAC1HDAC6 | |
| SCHEMBL11904869 | 0.77 | LMNA (0.55) | FDPSALDH1A1HDAC1HDAC6LMNA | |
| SCHEMBL10922695 | 0.76 | ALDH1A1 (0.46) | CCNB2CDK1CCNB1CCNB3FDPS | |
| SCHEMBL10995946 | 0.76 | ALDH1A1 (0.46) | CCNB2CDK1CCNB1CCNB3FDPS | |
| SCHEMBL5196533 | 0.76 | LMNA (0.57) | ALDH1A1HDAC1HDAC6LMNAMEN1 | |
| SCHEMBL5467578 | 0.75 | FDPS (0.39) | FDPSHDAC1HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115038702-A | Salt of arylamino purine derivative and preparation method and application thereof | 石药集团中奇制药技术（石家庄）有限公司 | 2022-09-09 | — | — | CN | claimed |
| WO-2021147996-A1 | SALT OF ARYLAMINOPURINE DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF | 石药集团中奇制药技术（石家庄）有限公司 | 2021-07-29 | — | — | WO | claimed |
| EP-2578584-B1 | ARYLAMINO PURINE DERIVATIVES, PREPARATION METHOD AND PHARMACEUTICAL USE THEREOF | SI CHUAN UNIV (CN) | 2020-08-12 | — | — | EP | claimed |
| US-9096601-B2 | Arylamino purine derivatives, preparation method and pharmaceutical use thereof | CSPC ZHONGQI PHARMACEUTICAL TECHNOLOGY (SHIJIAZHUANG) CO., LTD. (CN) | 2015-08-04 | — | — | US | claimed |
| US-20130203986-A1 | Arylamino Purine Derivatives, Preparation Method and Pharmaceutical Use Thereof | SI Chuaan University (CN) | 2013-08-08 | — | — | US | claimed |
| EP-2578584-A1 | ARYLAMINO PURINE DERIVATIVES, PREPARATION METHOD AND PHARMACEUTICAL USE THEREOF | Si Chuan University (CN) | 2013-04-10 | — | — | EP | claimed |
| US-20240115575-A1 | PHARMACEUTICAL COMPOSITION OF MULTI-TARGET PROTEIN KINASE INHIBITORS, AND USE THEREOF | CSPC ZHONGQI PHARMACEUTICAL TECHNOLOGY (SHIJIAZHUANG) CO., LTD (CN) | 2024-04-11 | — | — | US | disclosed |
| CN-117777135-A | Deuterated arylamino purine derivative and preparation method and application thereof | 石药集团中奇制药技术（石家庄）有限公司 | 2024-03-29 | — | — | CN | disclosed |
| CN-117777135-A | Deuterated arylamino purine derivative and preparation method and application thereof | 石药集团中奇制药技术（石家庄）有限公司 | 2024-03-29 | — | — | CN | disclosed |
| CN-117777135-A | Deuterated arylamino purine derivative and preparation method and application thereof | 石药集团中奇制药技术（石家庄）有限公司 | 2024-03-29 | — | — | CN | disclosed |
| EP-4272741-A1 | PHARMACEUTICAL COMPOSITION OF MULTI-TARGET PROTEIN KINASE INHIBITORS, AND USE THEREOF | CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. (CN) | 2023-11-08 | — | — | EP | disclosed |
| CN-115038702-A | Salt of arylamino purine derivative and preparation method and application thereof | 石药集团中奇制药技术（石家庄）有限公司 | 2022-09-09 | — | — | CN | disclosed |
| CN-115038702-A | Salt of arylamino purine derivative and preparation method and application thereof | 石药集团中奇制药技术（石家庄）有限公司 | 2022-09-09 | — | — | CN | disclosed |
| EP-2578584-A1 | ARYLAMINO PURINE DERIVATIVES, PREPARATION METHOD AND PHARMACEUTICAL USE THEREOF | Si Chuan University (CN) | 2013-04-10 | — | — | EP | disclosed |
| EP-2578584-A1 | ARYLAMINO PURINE DERIVATIVES, PREPARATION METHOD AND PHARMACEUTICAL USE THEREOF | Si Chuan University (CN) | 2013-04-10 | — | — | EP | disclosed |
| CN-103003278-A | Arylamino purine derivatives, preparation method and medical application thereof | CSPC ZHONGQI PHARMACEUTICAL TECHNOLOGY SHIJIAZHUANG CO LTD | 2013-03-27 | — | — | CN | disclosed |
| CN-103003278-A | Arylamino purine derivatives, preparation method and medical application thereof | CSPC ZHONGQI PHARMACEUTICAL TECHNOLOGY SHIJIAZHUANG CO LTD | 2013-03-27 | — | — | CN | disclosed |
| CN-103003278-A | Arylamino purine derivatives, preparation method and medical application thereof | CSPC ZHONGQI PHARMACEUTICAL TECHNOLOGY SHIJIAZHUANG CO LTD | 2013-03-27 | — | — | CN | disclosed |
| WO-2011147066-A1 | ARYLAMINO PURINE DERIVATIVES, PREPARATION METHOD AND PHARMACEUTICAL USE THEREOF | 四川大学 (CN) | 2011-12-01 | — | — | WO | disclosed |
| WO-2011147066-A1 | ARYLAMINO PURINE DERIVATIVES, PREPARATION METHOD AND PHARMACEUTICAL USE THEREOF | 四川大学 (CN) | 2011-12-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240115575-A1 | PHARMACEUTICAL COMPOSITION OF MULTI-TARGET PROTEIN KINASE INHIBITORS, AND USE THEREOF | DMPK, PRKCB, PRKCA | CCNB2 632/4885CDK1 228/4885CCNB1 765/4885 |
| US-20130203986-A1 | Arylamino Purine Derivatives, Preparation Method and Pharmaceutical Use Thereof | EGFR, PNP, GART | CCNB2 2296/4885CDK1 1410/4885CCNB1 1399/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.